Recent Finacing
Recent Raise
Adicet Bio is a preclinical biopharma developing allogeneic gamma‑delta T‑cell therapies, TCR‑like antibodies and peptide-target identification (Epitarget) to arm T cells and enable T‑cell engagers for tumors.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Adicet Bio.
